With the antibody drug conjugate market projected to hit $28 billion by 2028, some companies are looking to harness the drugs for immunotherapy. https://hubs.li/Q02FyS5B0
BioSpace’s Post
More Relevant Posts
-
Did you see our feature in this BioSpace article? In this piece, Hong I. Wan, CEO of Tallac Therapeutics, discusses the features of Tallac’s TAC-001, a TLR9 agonist ADC, and how it could potentially benefit a broader patient population with increased safety and tolerability. Read the full article here: https://lnkd.in/gi779jJu https://lnkd.in/gkWcfTXt
With the antibody drug conjugate market projected to hit $28 billion by 2028, some companies are looking to harness the drugs for immunotherapy. https://hubs.li/Q02FyS5B0
Drug Developers Tap the Immune System to Supercharge ADCs | BioSpace
biospace.com
To view or add a comment, sign in
-
Industry Spotlight: Antibody Drug Conjugates ADCs are a hot topic in the industry, with billions in acquisitions and deals recently announced. The Next Generation of ADCs will focus on payload and linker development, according to this article by Hayley Shasteen https://lnkd.in/eyZK2tmu At evitria, we're producing more and more biosimilars for ADC proof of concept studies - rapidly delivered, in your custom buffer, and at your specified concentration, these enable you to move straight into conjugation studies, and advance your program. With Enhertu - "an old antibody with an old linker with a different payload” - generating c. $2.4 Bn in revenue this year, there's no time to wait! Exploring ADCs? Get in touch with evitria for a confidential discussion: https://lnkd.in/eB4mcxN
Next-Generation ADCs Strive to Overcome Toxicities, Payload Problems | BioSpace
biospace.com
To view or add a comment, sign in
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Gene&Cell Therapy >> BioNTech pays $20M upfront for two monoclonal antibodies from China's WuXi Biologics: BioNTech is paying out $20 million upfront to another Chinese partner in exchange for the rights to develop two preclinical monoclonal antibodies, this time with CRDMO WuXi Biologics. The deal also includes research, development, regulatory and commercial milestone payments, plus tiered royalties for the Shanghai-based company, which will use its antibody discovery technology platforms to discover the antibodies. While the targets of the latest deal with WuXi are still undisclosed, BioNTech has been building up its presence in the cancer space after making a name as a top Covid mRNA vaccine developer, with TD Cowen’s Yaron Werber noting in November that BioNTech has assembled “one of the most extensive” oncology portfolios in biotech. During BioNTech’s Innovation Day in November, executives spent hours discussing data from a variety of antibody-drug conjugates, bispecifics, CAR-Ts and vaccines for cancer. The German biotech paid $55 million upfront to collaborate with Biotheus in November in return for the global ex-China license of PM8002, a bispecific simultaneously targeting PD-L1 and VEGF now being tested in Phase II studies in China. Biotheus could also get more than $1 billion more in milestone payments. BioNTech also partnered with Biotheus in July for a preclinical bispecific and a clinical-stage monoclonal antibody for undisclosed cancer targets in exchange for an upfront payment. Then in September, BioNTech started a Phase III trial for its antibody-drug conjugate aimed at patients with hormone receptor-positive, HER2-low breast cancer whose disease has progressed on at least two lines of prior endocrine therapies or within six months of first-line endocrine therapy and CDK4/6 inhibitor in the metastatic setting. That antibody-drug conjugate was licensed from China’s DualityBio for $170 million upfront last year. #lucidquest #genetherapy #celltherapy
BioNTech pays $20M upfront for two monoclonal antibodies from China's WuXi Biologics
https://endpts.com
To view or add a comment, sign in
-
Are you currently developing an Antibody Drug Conjugate (ADC) or Antibody Oligo Conjugate (AOC) or Antibody RNA Conjugate (ARC)? EirGenix’s latest blog post on "Current trends and innovations in the development of ADCs" discusses the current innovations and trends in the development of ADCs focusing on three main aspects: linker technology, drug payloads, and manufacturing. EirGenix along with its partner and key investor, Formosa Labs have the capabilities, experience, and regulatory credentials to help you be successful. This article and many more can be found on EirGenix’s Knowledge Platform (https://lnkd.in/gngj63j2). If you like what you read, help us spread the word! #ADC #ADCs #CDMO #mAb #CMO #EirGenix #FormosaLabs https://lnkd.in/dwzA8EjC
Current trends and innovations in the development of ADCs
resources.eirgenix.com
To view or add a comment, sign in
-
We are excited to announce a strategic agreement with WuXi Biologics to accelerate the development and manufacturing of IMIDomics IMB1001, a highly promising humanized antibody targeting CD226, a breakthrough target for treating #IMIDs. Through this agreement, WuXi Biologics will employ its state-of-the-art facilities, cutting-edge technology, and skilled scientific team to provide end-to-end support for the IMB1001 project. Our aim is to foster innovation, improve patient outcomes and ultimately address unmet medical needs for patients living with #IMIDs. This is a critical milestone for our lead program and fast-growing pipeline of IMID treatments, and represents a significant achievement for IMIDomics as we advance IMB1001 towards clinical development. Read more: https://lnkd.in/e4JPGMZs
IMIDomics Announces Strategic Agreement with WuXi Biologics to Advance IMB1001 Antibody Development for Immune-Mediated Inflammatory Diseases
businesswire.com
To view or add a comment, sign in
-
Linkers may be more important for ADCs than you think! This short article looks interesting to us. We do understand that ADCs are a fast-growing field. Thus, we take this opportunity to highly recommend a special collection of ADC papers published in our society’s official journal, Antibody Therapeutics (2022 CiteScore: 6.4). This special collection includes 14 excellent review and research ADC articles. Open access to collection at: https://lnkd.in/e76efmRZ. #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #adcs #adc #biologics
How Linker Technology Is Driving ADC Development
bioprocessonline.com
To view or add a comment, sign in
-
Are you currently developing an Antibody Drug Conjugate (ADC)? EirGenix’s latest blog post on "Current trends and innovations in the development of ADCs" discusses the current innovations and trends in the development of ADCs focusing on three main aspects: linker technology, drug payloads, and manufacturing. EirGenix along with its partner and key investor, Formosa Labs have the capabilities, experience, and regulatory credentials to help you be successful. This article and many more can be found on EirGenix’s Knowledge Platform (https://lnkd.in/gngj63j2). If you like what you read, please fill out the form to subscribe and help us spread the word! #ADC #ADCs #CDMO #mAb #CMO #EirGenix #FormosaLabs https://lnkd.in/dwzA8EjC
Current trends and innovations in the development of ADCs
resources.eirgenix.com
To view or add a comment, sign in
-
Using AI to speed up the drug development process...but does it work? It's going to be fascinating to see the role AI plays over the next few years/decades. A cancer drug by Johnson & Johnson helped in the article's example and AstraZeneca's VP of Data Science said "getting AI to crawl through lots of biomedical data has helped him and his team find a few drug targets they would not otherwise have considered". #ai #healthcare #pharmaceutical #drugdevelopment #infodesk https://lnkd.in/eQrGEag7
AI is dreaming up drugs that no one has ever seen. Now we’ve got to see if they work.
technologyreview.com
To view or add a comment, sign in
-
Here Thomas et al (Genentech) provides a unique 2 dimenshional analysis with deconjugation of small molecule payloads on antigen drug conjugates (ADC's) 🛎 Overview: Thomas et al online deconjugation was accomplished by in the autosampler via reduction of disulphide linker The small molecule and protein species when then seperates with the 1st dimension, size exclusion chromatography. The small molecule portion was then trapped and sent to the 2D for separation and quantification by reversed-phase liquid chromatography with identification of impurities and degradants by mass spectrometry. 🎯 Summary: Once the ADC sample and the reagents are placed inside the autosampler, Thomas et al automated process delivers the small molecule drug profile as the end result. Thomas et al method was shown to have excellent specificity, sensitivity, linearity, precision, accuracy. It was also successfully applied to characterize the small molecule drug on a panel of stressed ADC samples. #massspectrometry #massspec #biotech #biopharmaceuticals #biopharma #adc #chemistry #chemotherapy #cancer #cancercare #scienceandtechnology #science #pharmaindustry #chromatography #antibodydrugconjugates #antibodytherapeutics #drugdiscovery
Automated Online Deconjugation of Antibody-Drug Conjugate for Small Molecule Drug Profiling
sciencedirect.com
To view or add a comment, sign in